If approved by the Food and Drug Administration, GW Pharmaceuticals PLC’s cannabis-derived drug, which treats child epilepsy, would be the first of its kind in the U.S.
And while FDA approval is by no means a sure thing, U.K.-based GW GWP, -9.68% announced positive phase-three trial results for the drug, Epidiolex, Monday morning, sending its shares ballooning over 130%.
Read Full Article »